Media headlines about Radius Health (NASDAQ:RDUS) have been trending positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Radius Health earned a news impact score of 0.25 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 44.7672666378899 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
- Radius Health to Get Third Day-180 List of Outstanding Issues – Nasdaq (nasdaq.com)
- Wired News – Radius Health Expects CHMP to Issue Third Day-180 List of Outstanding Issues in Its Regulatory Review of Abaloparatide-SC (finance.yahoo.com)
- Radius Health (RDUS) Announces CHMP Will Issue Third Day-180 List of … (streetinsider.com)
- Radius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Will Issue a (nasdaq.com)
- Radius Health, Inc. (NASDAQ:RDUS) – Here’s What Long-Term Traders Should Know – Nasdaq Journal (press release) (nasdaqjournal.com)
Radius Health (RDUS) opened at $30.14 on Friday. Radius Health has a 52-week low of $24.66 and a 52-week high of $49.16. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53.
A number of research analysts have recently issued reports on the company. ValuEngine upgraded Radius Health from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. Citigroup assumed coverage on Radius Health in a research report on Wednesday, December 6th. They set a “neutral” rating and a $30.00 target price on the stock. Cantor Fitzgerald set a $58.00 target price on Radius Health and gave the company a “buy” rating in a research report on Friday, December 15th. BidaskClub lowered Radius Health from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 7th. Finally, Jefferies Group decreased their target price on Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $48.00.
In other news, VP Brent Hatzis-Schoch acquired 1,778 shares of the firm’s stock in a transaction on Friday, November 10th. The shares were bought at an average price of $28.09 per share, for a total transaction of $49,944.02. Following the acquisition, the vice president now owns 2,278 shares of the company’s stock, valued at approximately $63,989.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jesper Hoiland acquired 6,800 shares of the firm’s stock in a transaction on Tuesday, November 7th. The stock was purchased at an average price of $29.04 per share, for a total transaction of $197,472.00. Following the acquisition, the insider now directly owns 12,900 shares in the company, valued at approximately $374,616. The disclosure for this purchase can be found here. Insiders acquired a total of 158,578 shares of company stock worth $4,659,916 in the last 90 days. 15.00% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/22/radius-health-rdus-getting-positive-press-coverage-analysis-finds.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.